

# Sean Whittaker

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7646754/publications.pdf>

Version: 2024-02-01

94  
papers

11,560  
citations

94381

37  
h-index

51562

86  
g-index

95  
all docs

95  
docs citations

95  
times ranked

5508  
citing authors

#	ARTICLE	IF	CITATIONS
1	WHO-EORTC classification for cutaneous lymphomas. <i>Blood</i> , 2005, 105, 3768-3785.	0.6	3,529
2	Revisions to the staging and classification of mycosis fungoides and S�azary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). <i>Blood</i> , 2007, 110, 1713-1722.	0.6	1,243
3	Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. <i>Blood</i> , 2008, 111, 838-845.	0.6	617
4	Clinical End Points and Response Criteria in Mycosis Fungoides and S�azary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2598-2607.	0.8	550
5	TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and S�azary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). <i>Blood</i> , 2007, 110, 479-484.	0.6	452
6	Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. <i>Lancet</i> , The, 2017, 390, 555-566.	6.3	444
7	European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. <i>Blood</i> , 2008, 112, 1600-1609.	0.6	415
8	Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1192-1204.	5.1	398
9	EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma*. <i>Blood</i> , 2011, 118, 4024-4035.	0.6	365
10	European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/S�azary syndrome â€“ Update 2017. <i>European Journal of Cancer</i> , 2017, 77, 57-74.	1.3	363
11	Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. <i>British Journal of Dermatology</i> , 2003, 149, 1095-1107.	1.4	220
12	Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sezary syndrome and mycosis fungoides. <i>British Journal of Dermatology</i> , 2002, 147, 464-475.	1.4	153
13	Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. <i>Blood</i> , 2001, 97, 624-630.	0.6	142
14	How I treat mycosis fungoides and S�azary syndrome. <i>Blood</i> , 2016, 127, 3142-3153.	0.6	138
15	Absence of the t(14;18) chromosomal translocation in primary cutaneous B-cell lymphoma. <i>British Journal of Dermatology</i> , 2001, 144, 735-744.	1.4	133
16	The PROCLIPi international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. <i>British Journal of Dermatology</i> , 2019, 181, 350-357.	1.4	127
17	A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. <i>European Journal of Cancer</i> , 2013, 49, 2859-2868.	1.3	121
18	IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1160-1170.	5.1	119

#	ARTICLE	IF	CITATIONS
19	British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. British Journal of Dermatology, 2019, 180, 496-526.	1.4	111
20	Evidence-based practice of photopheresis 1987-2001: a report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma Group. British Journal of Dermatology, 2006, 154, 7-20.	1.4	108
21	Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell) Tj ETQq1 1.0.784314 rgBT / 1.2 103	1.2	103
22	Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Annals of Oncology, 2017, 28, 2517-2525.	0.6	98
23	Bexarotene therapy for mycosis fungoides and SÅ©zary syndrome. British Journal of Dermatology, 2009, 160, 1299-1307.	1.4	96
24	Prospective International Multicenter Phase II Trial of Intravenous Pegylated Liposomal Doxorubicin Monochemotherapy in Patients With Stage IIB, IVA, or IVB Advanced Mycosis Fungoides: Final Results From EORTC 21012. Journal of Clinical Oncology, 2012, 30, 4091-4097.	0.8	94
25	Aggressive epidermotropic cutaneous <sup>8</sup> lymphoma: a cutaneous lymphoma with distinct clinical and pathological features. Report of an <sup>EORTC</sup> Cutaneous Lymphoma Task Force Workshop. Histopathology, 2015, 67, 425-441.	1.6	86
26	U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. British Journal of Dermatology, 2013, 168, 192-200.	1.4	81
27	Evaluation of Immunophenotypic and Molecular Biomarkers for SÅ©zary Syndrome Using Standard Operating Procedures: A Multicenter Study of 59 Patients. Journal of Investigative Dermatology, 2016, 136, 1364-1372.	0.3	78
28	Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma		

#	ARTICLE	IF	CITATIONS
37	Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. <i>Blood Advances</i> , 2021, 5, 5098-5106.	2.5	46
38	Cutaneous necrosis associated with the antiphospholipid syndrome and mycosis fungoides. <i>British Journal of Dermatology</i> , 1994, 130, 92-96.	1.4	44
39	Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIP) study*. <i>British Journal of Dermatology</i> , 2021, 184, 722-730.	1.4	39
40	Coexistent cutaneous T-cell lymphoma and B-cell chronic lymphocytic leukaemia. <i>British Journal of Dermatology</i> , 1992, 127, 519-523.	1.4	36
41	Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma. <i>British Journal of Cancer</i> , 2013, 109, 2566-2573.	2.9	35
42	"We're all carrying a burden that we're not sharing": a qualitative study of the impact of cutaneous T-cell lymphoma on the family. <i>British Journal of Dermatology</i> , 2015, 172, 1581-1592.	1.4	32
43	"We had to change to single beds because I itch in the night": a qualitative study of the experiences, attitudes and approaches to coping of patients with cutaneous T-cell lymphoma. <i>British Journal of Dermatology</i> , 2015, 173, 83-92.	1.4	31
44	Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. <i>European Journal of Cancer</i> , 2021, 148, 411-421.	1.3	27
45	Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma. <i>Biomarker Research</i> , 2014, 2, 16.	2.8	26
46	Results of a 5-Week Schedule of Modern Total Skin Electron Beam Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 936-941.	0.4	25
47	Lymphomatoid papulosis in a patient with atopic eczema on long-term ciclosporin therapy. <i>British Journal of Dermatology</i> , 2005, 152, 1346-1348.	1.4	22
48	Molecular Genetics of Cutaneous Lymphomas. <i>Annals of the New York Academy of Sciences</i> , 2001, 941, 39-45.	1.8	21
49	Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. <i>European Journal of Cancer</i> , 2020, 133, 120-130.	1.3	21
50	Biological Insights into the Pathogenesis of Cutaneous T-Cell Lymphomas (CTCL). <i>Seminars in Oncology</i> , 2006, 33, 3-6.	0.8	20
51	Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 637-643.	0.2	19
52	Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIP) international study*. <i>British Journal of Dermatology</i> , 2021, 184, 524-531.	1.4	18
53	Adjuvant therapy in melanoma. <i>Clinical and Experimental Dermatology</i> , 2000, 25, 497-502.	0.6	16
54	A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. <i>European Journal of Dermatology</i> , 2017, 27, 286-294.	0.3	16

#	ARTICLE	IF	CITATIONS
55	Anti-CCR4 Monoclonal Antibody, Mogamulizumab, Demonstrates Significant Improvement in PFS Compared to Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): Results from the Phase III MAVORIC Study. <i>Blood</i> , 2017, 130, 817-817.	0.6	15
56	â€˜It's a traumatic illness, traumatic to witnessâ€™: a qualitative study of the experiences of bereaved family caregivers of patients with cutaneous T-cell lymphoma. <i>British Journal of Dermatology</i> , 2018, 179, 882-888.	1.4	13
57	Systematic Assessment of Potential Cardiac Effects of the Novel Histone Deacetylase (HDAC) Inhibitor Romidepsin. <i>Blood</i> , 2009, 114, 3709-3709.	0.6	13
58	Clinical, histopathological and prognostic features of primary cutaneous acral <sup>+</sup> Tâ€cell lymphoma and other dermal <sup>+</sup> cutaneous lymphoproliferations: results of an <sup>+</sup> EORTC</sup> Cutaneous Lymphoma Group workshop*. <i>British Journal of Dermatology</i> , 2022, 186, 887-897.	1.4	12
59	Temozolomide for central nervous system involvement in mycosis fungoides. <i>International Journal of Dermatology</i> , 2016, 55, 751-756.	0.5	11
60	International multicenter phase II study of the HDAC inhibitor (HDACi) depsipeptide (FK228) in cutaneous T-cell lymphoma (CTCL): Interim report. <i>Journal of Clinical Oncology</i> , 2006, 24, 3063-3063.	0.8	11
61	Phenytoin-induced toxic epidermal necrolysis: a case report. <i>Clinical and Experimental Dermatology</i> , 1996, 21, 116-120.	0.6	10
62	Folliculotropic mycosis fungoides (stage IIA) progressing to SÃ©zary syndrome: a case report. <i>British Journal of Dermatology</i> , 2008, 159, 1197-9.	1.4	10
63	Vorinostat in combination with bexarotene in advanced cutaneous T-cell lymphoma: A phase I study. <i>Journal of Clinical Oncology</i> , 2009, 27, 8572-8572.	0.8	10
64	Primary cutaneous CD30<sup>+</sup> anaplastic large-cell lymphoma associated with fingolimod. <i>British Journal of Dermatology</i> , 2018, 179, 1400-1401.	1.4	9
65	Flow cytometry for the assessment of blood tumour burden in cutaneous Tâ€cell lymphoma: towards a standardized approach. <i>British Journal of Dermatology</i> , 2022, 187, 21-28.	1.4	9
66	Global Patterns of Methylation in SÃ©zary Syndrome Provide Insight into the Role of Epigenetics in Cutaneous T-Cell Lymphoma. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1753-1754.	0.3	8
67	U.K. national audit of extracorporeal photopheresis in cutaneous T-cell lymphoma. <i>British Journal of Dermatology</i> , 2018, 178, 569-570.	1.4	8
68	Clinically Significant Responses Achieved with Romidepsin in Treatment-Refractory Cutaneous T-Cell Lymphoma: Final Results from a Phase 2B, International, Multicenter, Registration Study. <i>Blood</i> , 2008, 112, 263-263.	0.6	8
69	Increased Expression of PLS3 Correlates with Better Outcome in SÃ©zary Syndrome. <i>Journal of Investigative Dermatology</i> , 2017, 137, 754-757.	0.3	7
70	First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody, in Relapsed/Refractory Cutaneous T-Cell Lymphomas: Preliminary Safety, Exploratory and Clinical Activity Results. <i>Blood</i> , 2016, 128, 1826-1826.	0.6	6
71	Diffuse large B-cell lymphoma developing in erythrodermic cutaneous T-cell lymphoma: a case series. <i>British Journal of Dermatology</i> , 2017, 177, e138-e140.	1.4	4
72	Nonhealing surgical wound due to cutaneous malakoplakia. <i>Clinical and Experimental Dermatology</i> , 2017, 42, 123-125.	0.6	4

#	ARTICLE	IF	CITATIONS
73	Erythroderma is not all psoriasis: a case of SÅ©zary syndrome. British Journal of Hospital Medicine (London, England: 2005), 2014, 75, 50-51.	0.2	2
74	BRENTUXIMAB VEDOTIN VS PHYSICIAN'S CHOICE IN CTCL PATIENTS FROM THE PHASE 3 ALCANZA STUDY: ANALYSIS OF OUTCOMES BY CD30 EXPRESSION. Hematological Oncology, 2017, 35, 77-78.	0.8	2
75	PATIENTâ€™REPORTED OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA: RESULTS FROM THE PHASE 3 ALCANZA STUDY. Hematological Oncology, 2017, 35, 247-248.	0.8	2
76	FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30-POSITIVE (CD30+) CUTANEOUS T-CELL LYMPHOMA (CTCL). Hematological Oncology, 2019, 37, 286-288.	0.8	2
77	Romidepsin (Depsipeptide, FK228) Induces Clinically Significant Responses in Treatment-Refractory CTCL: Interim Report of a Phase II Multicenter Study.. Blood, 2006, 108, 2468-2468.	0.6	2
78	Characterization of Cyclic Hematologic Changes Observed in Patients with Cutaneous T-Cell Lymphoma (CTCL) Receiving Romidepsin, a Novel Histone Deacetylase (HDAC) Inhibitor.. Blood, 2009, 114, 3701-3701.	0.6	2
79	Responses to Romidepsin in Patients with Cutaneous T-Cell Lymphoma (CTCL) and Prior Treatment with Systemic Chemotherapy: Subanalysis from the Pivotal Phase 2 Study. Blood, 2014, 124, 4451-4451.	0.6	2
80	Clinically Significant Responses Achieved with Romidepsin in 37 Patient with Cutaneous T-Cell Lymphoma (CTCL) with Blood Involvement.. Blood, 2009, 114, 2683-2683.	0.6	2
81	A Cutaneous Lymphoma International Consortium â€™CLICâ€™™ study of Prognostic Parameters in Advanced Stages of Mycosis Fungoides and Sezary Syndrome: Progress Towards Establishing a Prognostic Index to Augment Clinical Staging. Blood, 2014, 124, 1621-1621.	0.6	2
82	Pustular psoriasis in pregnancy, and prednisolone. Journal of Dermatological Treatment, 1995, 6, 5-7.	1.1	1
83	A Cutaneous T-Cell Lymphoma EORTC Trials Platform. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, S90-S92.	0.2	1
84	RESPONSE BY STAGE IN CD30-POSITIVE (CD30+) CUTANEOUS T CELL LYMPHOMA (CTCL) PATIENTS RECEIVING BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN THE PHASE 3 ALCANZA STUDY. Hematological Oncology, 2017, 35, 245-247.	0.8	1
85	Whole Exome Sequencing of Flow Purified Tumour Cells Reveals Recurrently Mutated Genes and Pathways in Adult T-Cell Lymphoma/Leukaemia (ATLL). Blood, 2015, 126, 1469-1469.	0.6	1
86	Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011.. Journal of Clinical Oncology, 2012, 30, 8076-8076.	0.8	1
87	Clinical and Prognostic Significance of Molecular Studies in Cutaneous T-Cell Lymphoma. Current Topics in Pathology Ergebnisse Der Pathologie, 2001, 94, 93-101.	0.2	1
88	EORTC 21012: Phase II Multicentre Study of Caelyxâ€™,¢ Monotherapy In Patients with Advanced Mycosis Fungoides Stage IIb, Iva and IVb with or without Previous Chemotherapy.. Blood, 2010, 116, 2823-2823.	0.6	1
89	Cutaneous lymphoma. , 2001, , 233-251.		0
90	Multiple cutaneous, oropharyngeal and pulmonary nodules. British Journal of Dermatology, 2015, 173, 540-543.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Violaceous facial nodules. <i>Clinical and Experimental Dermatology</i> , 2020, 45, 642-645.	0.6	0
92	Management of Late Stage Cutaneous T-cell lymphoma. <i>Clinical and Experimental Dermatology</i> , 2001, 26, 216-217.	0.6	0
93	The EORTC Cutaneous T-Cell Lymphoma (CTCL) Platform. <i>Blood</i> , 2010, 116, 4896-4896.	0.6	0
94	First-in-human, open label, multicenter phase I of IPH4102, first-in-class humanized anti-KIR3DL2 monoclonal antibody, in relapsed/refractory cutaneous T-cell lymphomas.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS2591-TPS2591.	0.8	0